Skip to main
WVE
WVE logo

WVE Stock Forecast & Price Target

WVE Analyst Ratings

Based on 10 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

WAVE Life Sciences Ltd's innovative RNA-targeting modalities, including RNA editing and antisense silencing, position the company to address both rare and prevalent diseases, creating a broad market potential for its therapies. Positive data from ongoing programs, particularly relating to the INHBE/ALK7 pathway for obesity treatment, is expected to validate the company's therapeutic platform and enhance investor confidence. Anticipated initial data from the Phase 1 study of WVE-007 in 2025, alongside robust safety profiles and the effectiveness of infrequent dosing, further support a favorable outlook on the biotechnology firm's growth potential in the RNA medicine sector.

Bears say

WAVE Life Sciences Ltd faces significant risks that negatively impact its stock outlook, primarily centered around the potential failure of its clinical candidates WVE-004 and WVE-N531 in ongoing studies and the subsequent inability to secure regulatory approval. Furthermore, the company risks falling short of peak commercial revenue estimates for WVE-003 and WVE-N531, which may result from constraints related to market size, penetration, and pricing strategies. Data indicating an altered macrophage response to treatment, alongside challenges in demonstrating robust therapeutic efficacy, further complicate the company's ability to capitalize on its RNA medicines platform and achieve sustainable growth.

WVE has been analyzed by 10 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Wave Life Sciences and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Wave Life Sciences (WVE) Forecast

Analysts have given WVE a Buy based on their latest research and market trends.

According to 10 analysts, WVE has a Buy consensus rating as of Dec 4, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $18.90, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $18.90, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Wave Life Sciences (WVE)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.